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Abstract
Background & Aims: Gastrointestinal peptides are increasingly being linked to processes controlling the maintenance of
bone mass. Peptide YY (PYY), a gut-derived satiety peptide of the neuropeptide Y family, is upregulated in some states that
also display low bone mass. Importantly, PYY has high affinity for Y-receptors, particularly Y1R and Y2R, which are known to
regulate bone mass. Anorexic conditions and bariatric surgery for obesity influence circulating levels of PYY and have a
negative impact on bone mass, but the precise mechanism behind this is unclear. We thus examined whether alterations in
PYY expression affect bone mass.
Methods: Bone microstructure and cellular activity were analyzed in germline PYY knockout and conditional adult-onset
PYY over-expressing mice at lumbar and femoral sites using histomorphometry and micro-computed tomography.
Results: PYY displayed a negative relationship with osteoblast activity. Male and female PYY knockout mice showed
enhanced osteoblast activity, with greater cancellous bone mass. Conversely, PYY over-expression lowered osteoblast
activity in vivo, via a direct Y1 receptor mediated mechanism involving MAPK stimulation evident in vitro. In contrast to PYY
knockout mice, PYY over expression also altered bone resorption, as indicated by greater osteoclast surface, despite the lack
of Y-receptor expression in osteoclastic cells. While evident in both sexes, cellular changes were generally more pronounced
in females.
Conclusions: These data demonstrate that the gut peptide PYY is critical for the control of bone remodeling. This regulatory
axis from the intestine to bone has the potential to contribute to the marked bone loss observed in situations of extreme
weight loss and higher circulating PYY levels, such as anorexia and bariatric obesity surgery, and may be important in the
maintenance of bone mass in the general population.
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Introduction
Osteoporosis is a serious health condition presenting a major
economic burden on health care systems worldwide. It is estimated
that osteoporotic fracture will occur in one in two women and one
in three men over the age of 60 [1]. While the etiology of
osteoporosis has been viewed primarily in light of endocrine
factors originating from the hypothalamo-pituitary axis, in recent
years a novel endocrine axis has emerged involving peptides
released from the gut [2]. Indeed, in addition to its roles in
regulating energy homeostasis and appetite [3,4], glucose metab-
olism [5], the neural system [6] and factors associated with higher
functions such as mood and depression [7], the gut is emerging as
a fundamental regulator of bone health. It is becoming increas-
ingly apparent that a more detailed appreciation of the gastroin-
testinal/bone interface is vital for an up-to-date understanding of
skeletal regulation, and the endocrine actions of the gut.
In light of the widespread health issues associated with
osteoporosis, it is concerning that significant loss of bone is also
evident in younger individuals in association with altered energy
homeostasis. In particular, the low bone mass of anorexia nervosa,
and the marked bone loss observed post-bariatric surgery illustrate
the powerful relationship between food intake and bone. While it
is known that weight reduction associated with anorexia nervosa
and bariatric surgery leads to bone loss [8,9], it is increasingly
recognized that additional pathways contribute to the loss of bone
resulting from altered nutritional status. Indeed, studies post
bariatric surgery have reported that weight accounted for as little
as 14% of the loss of bone mineral content, indicating a significant
contribution by non-weight bearing factors [10].
Recent literature from human studies suggests that a ligand of the
neuropeptide Y family, the gut hormone peptide YY (PYY), may
play an important role in regulation of bone mass, particularly
under conditions of altered energy balance [11,12,13,14]. PYY,
PLoS ONE | www.plosone.org 1 July 2012 | Volume 7 | Issue 7 | e40038
predominantly expressed in L cells in the mucosa of the ileum and
colon [15], is an important component of the energy homeostatic
system. Released post-prandially into the bloodstream in proportion
to calorie intake, PYY acts to inhibit food intake and increase satiety
[16]. Importantly, altered PYY levels are associated with several
metabolic disorders which also alter bone mass, indicating a possible
role for PYY in bone homeostasis. For instance, the greater
circulating PYY levels in patients with anorexia nervosa are
significantly associated with altered bone homeostasis and dimin-
ished bone mass [11], particularly in the spine [14]. Elevated PYY
levels are a negative predictor of the bone formation serum marker,
pro-collagen type I N-terminal pro-peptide (PINP) and lumbar
spine bone mineral density in amenorrheic athletes [12]. Converse-
ly, obesity is associated with lower levels of PYY [17] and greater
bone mineral density [18]. However, one of the biggest changes in
PYY levels is observed in patients following some forms of bariatric
surgery, such as Roux-en-Y gastric bypass and gastric sleeve
[19,20], with higher post-prandial PYY levels compared to pre-
surgery. Significant bone loss is also observed in obese patients
following bariatric surgery [21]. However, following gastric
banding, which does not alter PYY levels [22], bone loss is less
pronounced [23,24], indicating that PYY may represent a
component of the non-weight related mechanisms reducing bone
mass in these patients. Importantly, PYY may play a broader role in
the maintenance of bone mass. A recent cross-sectional study in
healthy premenopausal women demonstrated that PYY levels have
a significant, negative association with total body and hip bone mass
[13], explaining nearly 9% of the variance in hip bone mineral
density in these women. Thus it is clear that a greater understanding
of the relationship between PYY and bone is required, particularly
with regard to the skeletal effect of elevated PYY levels.
Although evidence of a negative correlation between PYY levels
and bone mass is emerging, this relationship is at present based on
associations and is confounded by factors such as body mass index
[18] and gonadal status [25]. Therefore in this study, the role of
PYY on bone homeostasis was examined in mouse models with
either germline PYY knockout or adult-onset conditional PYY
over-expression, to assess the impact of the absence or excess of
PYY, respectively, on the skeleton.
Materials and Methods
Animals
All research and animal care procedures were approved by the
Garvan Institute/St Vincent’s Hospital Animal Experimentation
Ethics Committee. Mice were housed at 22uC with a 12 h light/
dark cycle. Mice had ad libitum access to water and standard chow
(8% calories from fat, 21% calories from protein, 71% calories
from carbohydrate, 2.6 kcal/g; Gordon’s Speciality Stock Feeds,
Yanderra, Australia). Generation of PYY knockout mice was
described previously [26]. Briefly, a 10.5 kb SpeI fragment
containing 6 kb 59-flanking sequence, the entire PYY gene and
a 3 kb 39-flanking sequence was used for the construction of a
PYY-Cre knock-in construct. The linearized clone was transfected
into ES cells derived from 129 Sv/J mice. Two positive clones
were injected into C57BL/6 blastocysts, chimeric mice were bred
to generate homozygous PYY-Cre knock-in mice.
PYY Transgene Construct and Generation of Adult-onset
PYY Over-expression Model (PYYtg)
A tamoxifen-inducible, CMV-driven Cre transgenic mouse
model (Rosa-CreERT2) was obtained from the Jackson Laboratory
(Bar Harbor, ME) [27]. Heterozygous Rosa-CreERT2 transgenic
mice were crossed with homozygous PYY transgenic mice
(PYYlox/lox) to generate PYY over-expressing (here called PYYtg)
and non-PYY over-expressing littermate controls (here called
WT). The PYYlox/lox mice have the PYY gene inserted into the
ubiquitously expressed Rosa26 locus with a CMV promoter and a
transcriptional stop cassette flanked by loxP sites. Therefore, in
mice with the genotype of PYYlox/CreERT2 (PYYtg), tamoxifen
treatment activates Cre-recombinase, which leads to the removal
of the lox flanked stop cassette in front of the PYY gene bringing
the CMV promoter in close proximity to the PYY gene and induce
the over-expression of PYY. Littermate controls that carried only
the PYYlox/lox locus but no RosaCre were used as controls (WT).
Tamoxifen (40 mg/g of body weight) was i.p. injected twice at 10
weeks of age, 3 days apart, and tissues were collected 6 weeks later.
Genotyping used genomic DNA isolated from tail tissue,
confirmed later with liver DNA. PCR amplification of the
fragment encompassing the stop cassette of the PYY transgene
construct was performed using LacZ-F/Neo-RZ primers. Primer
sequence, PCR conditions and expected product size for each
primer pair are summarized in Table S1. Deletion of the stop
cassette of the PYY transgene from tamoxifen-injected mice was
confirmed with the mPYYtg-CMV/mPYY-W primers, producing
a 150 bp product if the loxP flanked stop cassette has been deleted.
RNA Extraction, Reverse Transcription-PCR (RT-PCR) and
Quantitative Real-time PCR (qPCR)
Total RNA from liver and brain (hypothalamic and extra-
hypothalamic tissue) of wildtype and PYYtg mice were isolated
using TrizolH Reagent (Sigma) following the manufacturer’s
protocol. Total RNA was treated with DNase I (Ambion, Austin,
TX, USA) before reverse transcription using Superscript III First-
Strand Synthesis System (Invitrogen, Mount, Waverley, VIC,
Australia), following the manufacturer’s protocol.
Expression of PYY mRNA was first determined using RT-PCR
with GAPDH as control (Table S1). PYY mRNA expression was
further examined by qPCR (LightCyclerH 480, Roche Applied
Science, Germany) using SensiMixTM Probe (Bioline Australia Pty
Ltd, Alexandria, NSW, Australia) with gene-specific primers. To
control for variability in amplification due to differences in starting
mRNA concentrations, ribosomal protein L19 (RPL-19) was used
as an internal standard. The relative expression of PYY mRNA
was computed using the comparative Ct method for relative
quantification (Sequence Detection Systems Chemistry Guide,
Applied Biosystems).
Immunohistochemical Analysis of the Pancreas
PYY IHC was performed on two random 5 mm paraformalde-
hyde-fixed, paraffin-embedded pancreatic sections, as described
previously [26]. Briefly, whole pancreas, fixed in 4% PBS-buffered
paraformaldehyde overnight at 4uC before being processed and
embedded in paraffin. Slides were incubated in 0.3% H2O2 in
ethanol for 35 min, rinsed in PBS and blocked with 10% normal
horse serum in PBS for 20 min at room temperature. Excess
blocking solution was removed before incubating with our in-
house monoclonal mouse PYY antiserum (diluted 1:1000)
overnight at 4uC. Slides were rinsed in PBS before incubation
with goat anti-mouse IgG-biotin conjugated antibody (Sigma)
(diluted 1:1000) for 30 min at room temperature. Sections were
rinsed in PBS and incubated for 30 min with ExtrAvidinH-
Peroxidase (Sigma) (diluted 1:250) at room temperature. After
washing with PBS, immunoperoxidase staining was performed by
treating the sections with diaminobenzidine (DAKO Corp.,
Carpinteria, California, USA) for 3 min. Slides were counter-
stained with haematoxylin, then dehydrated through graded
ethanols and xylene before coverslipping.
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Bone Densitometry
Whole body bone mineral density (BMD) and bone mineral
content (BMC) were measured with mice ventral side down (head
and tail inclusion), using a dedicated mouse dual energy X-ray
absorptiometer (DXA) (Lunar Piximus II, GE Medical Systems,
Madison WI), as previously described [28].
Tissue Collection and Bone Histomorphometry
For tissue collection, germline PYY knockout mice were culled at
14 weeks, PYY transgenic mice were culled at 16 weeks of age, 6
weeks after transgene induction. Mice were sacrificed by cervical
dislocation and decapitation between 12.00–17.00 h for collection of
trunk blood. Both femora were excised and fixed in 4% PBS-
buffered paraformaldehyde for 16 h at 4uC. Right femora were
bisected transversely at the midpoint of the long axis. After
dehydration, distal halves were embedded undecalcified in methyl-
methacrylate (Medim-Medizinische Diagnostik, Giessen, Germany).
Sagittal 5 mm sections were stained and evaluated as previously
[29]. Analysis of cancellous bone volume (BV/TV, %), trabecular
thickness (Tb.Th, mm), and number (Tb.N,/mm) was carried out
on modified von Kossa stained sections. To assess bone formation
indices, s.c. calcein (20 mg/kg) (Sigma Chemical Company, St
Louis, USA) was given 10 and 3 days prior to collection.
Mineralizing surface (MS, %) and mineral apposition rate
(MAR, mm/d) were measured from unstained sections, and bone
formation rate was calculated (BFR = MS/BS *MAR, mm2/mm/d)
[29]. Bone resorption indices, osteoclast surface (Oc.S, %) and
number (Oc.N,/mm), were estimated in tartrate-resistant acid
phosphatase stained sections [30]. All cancellous measurements
were conducted in a sample area bordering the epiphyseal growth
plate, beginning 0.25 mm proximal to the mineralization zone and
extending proximally by 4.2 mm, encompassing all the cancellous
bone within the cortices [31]. Cortical mineral apposition rate was
measured at the posterior endosteal mid-shaft, extending 1000 mm
proximal from the mid-femora.
Micro-computed Tomography (Micro-CT)
A Skyscan 1174 scanner and associated analysis software
(Skyscan, Aartselaar, Belgium) were used to examine 3-dimen-
sional bone structure as previously described [32]. Following
fixation, bone was scanned in a plastic tube filled with 70%
ethanol. A 0.5 mm aluminum filter was applied to the 50 kV X-
ray source, exposure time of 3600 ms and sharpening at 40%.
Distal femora were scanned at a 6.2 mm pixel resolution acquired
over an angular range of 180u, with a rotation step of 0.4u.
Following reconstruction, cortical bone analyses were carried out
in 150 slices (0.93 mm) starting 4.5 mm proximal from the distal
growth plate using CT-Analyser software (Skyscan). In PYYtg
mice, femur length was different between genotypes, thus cortical
bone region was adjusted for femur length. For vertebrae, slices
between the rostral and caudal growth-plates were selected, with
10 slices offset from the rostral growth-plate and 25 slices offset
from the caudal growth-plate. The vertebrae body (L3) was then
subdivided into cancellous and cortical components by manual
tracing.
Isolation of Calvarial Osteoblastic Cells
Primary calvarial osteoblasts were isolated as previously
described [33]. Briefly, five calvaria from six-day-old mice were
then digested using 0.1% Collagenase and 0.2% Dispase II a-
MEM without FCS and were shaken for 10 min at 37uC. After
incubation the liquid phase, was discarded. This was repeated,
adding 1 ml of digestion medium, but the liquid (fraction 2) was
collected. This was repeated 4 times. The cells from fractions 2 to
5 were pooled by centrifugation (5 min, 500 g). The pellet was re-
suspended in 1 ml a-MEM. The cells were seeded and cultured in
6-well plates. 1.5 ml of a-MEM culture medium containing 10%
FCS and antibiotics and 1 ml of cell suspension was added and
grown at 37uC in 5% CO2 in air. The medium was replaced every
3 days. The medium was pre-warmed to 37uC before changing.
The cells were grown until sub-confluent, trypsinized and plated in
24-well plates.
Stimulation, Protein Extraction and Western blotting
Primary calvarial cells were serum starved overnight (0.5% FBS)
and treated with 50 nM PYY with or without 1 mM of the Y1
receptor antagonist 1229U91 [34] (Sigma-Aldrich) for the
indicated times. Protein extracts were prepared as previously
described [35]. Proteins were electrophoresed on a 10% SDS
polyacrylamide gels, transferred to nitrocellulose membrane and
probed with p44/42 MAPK (Erk1/2) antibody (Cell Signaling
Technology). Anti-mouse/rabbit IgG HRP conjugate (Promega)
was used as a secondary antibody. Bands were detected by ECL
(GE Healthcare Australia). Densitometric analysis of western blots
were performed using ImageJ software (http://rsbweb.nih.gov/ij/)
quantifying mean gray values subtracted from background.
Total RNA Extraction and RT-PCR of Bone Marrow
Monocytes (BMM) and RANKL-Induced Osteoclasts
Age and sex matched WT (C57BL/6) mice were sacrificed and
hindlimbs were dissected. The bone marrow was flushed from the
tibia and femur with a 21G needle syringe in a-MEM and the cells
were resuspended in fresh complete a-MEM (10% FCS, Pen-
Strep, GlutaMax) with 10 ng/ml human M-CSF (R&D systems)
for BMM culture for three days in T-75 flasks. Non-adherent cells
were discarded through media changes. Adherent cells were
released by trypsin and seeded at a density of 56104 cells per well
in 6-well plates. A RANKL time course was performed at the
allocated time points (0, 2, 3, 4, 5 days) with 50 ng/ml murine
sRANKL (Peprotech). Total RNA was isolated using Trizol
Reagent (Invitrogen) according to manufacturer instructions and
Reverse Transcription was performed using the Superscript III
First-Strand Synthesis System (Invitrogen). RT-PCR was per-
formed with the cyclic conditions: 94uC, 40 sec; 55uC, 40 sec;
72uC, 45 sec for 30 cycles with the following primers: GAPDH,
Forward: ACTTTGTCAAGCTCATTTCC, Reverse: TGCA-
GCGAACTTTATTGATG; Y1R, Forward: CTCGCTGGTT-
CTCATCGCTGTGGAACGG, Reverse: GCGAATGTATAT-
CTTGAAGTAG; Y2R, Forward: TCCTGGATTCCTCATCT-
GAG, Reverse: GGTCCAGAGCAATGACTGTC; Y4R, For-
ward: TCTACAGACAGTAGACCAGG, Reverse: GTAGG-
TTGGTCACATTGGAC; Y5R, Forward: GGGCTCTATA-
CATTTGTAAGTCTTCTGGG, Reverse: CATGGCTTTGC-
CGAACATCCACTGATCC; y6R, Forward: GGAGGGATG-
GTTATTGTGAC, Reverse: GTTGTTGCTCTTGCCACTGG;
Cathepsin K, Forward: GGGAGAAAAACCTGAAGC, Reverse:
ATTCTGGGGACTCAGAGC; Calcitonin Receptor, Forward:
TGGTTGAGGTTGTGCCCA, Reverse: CTCGTGGGTTTG-
CCTCATC. PCR products were analyzed by agarose gel
electrophoresis.
MTS Cell Proliferation Assay on Bone Marrow Stromal
Cells (BMSCs)
Age and sex matched WT and germline Y1R2/2 mice were
sacrificed and hindlimbs were dissected for bone marrow
extraction. The bone marrow was flushed from the tibia and
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femur with a 21G needle syringe in a-MEM and the cells were
resuspended in fresh complete a-MEM (10% FCS, Pen-Strep,
GlutaMax) and cultured for seven days in T-75 flasks or 10 cm
dishes. Media was changed every two days to remove non-
adherent cells. After seven days of culture, the cells were
trypsinized and plated at 86103 cells per well in 96-well plates
to be cultured for two days before differentiation in osteogenic
media (50 mg/ml Ascrobic acid, 10 mM b-glycerophosphate) with
25–100 nM concentrations of hPYY 1–36aa (Sigma) for 5 days.
The Promega CellTiter 96H AQueous MTS cell proliferation
assay (Cat# G5421) was used according to manufacturer protocol
(Promega). Briefly, osteogenic media was replaced with complete
a-MEM before 20 ml of MTS-PMS reagent was added per well
(100 ml of media) and incubated for four hours at 37uC. Cell free
wells were used as blanks. Absorbance at 490 nm was quantified
by spectrophotometer.
Statistical Analysis
Data are expressed as means 6 standard error (SEM).
Differences between genotypes were assessed by two-tailed
students T-test using GraphPad Prism 5 (Version 5.0a, GraphPad
Software, Inc). For all statistical analyses, p values below 0.05 were
considered statistically significant.
Results
Lack of PYY Leads to Greater Bone Formation in Mice
In order to investigate the effect of PYY deficiency on bone in
the absence of any confounding effects on body weight, knockout
mice at the age of 14 weeks were studied, prior to the onset of
greater body weight [26]. Dual energy X-ray absorptiometry
(DXA) revealed greater whole body BMD and BMC in PYY2/2
mice compared to wild-type controls, significantly so in females
(Figure 1A, B). In the lumbar vertebrae, PYY2/2 mice of both
genders exhibited significantly greater BMD and BMC than wild-
type, without significant differences in femur length and lumbar
vertebral height between genotypes (data not shown). Histomor-
phometric analysis revealed significantly greater cancellous bone
volume in PYY2/2 mice of both genders at the distal femoral
metaphysis, as evident in tissue sections stained for mineralized
tissue (Figure 1C, D). In female mice, PYY deletion also increased
cancellous bone volume in the lumbar vertebral body as measured
by mCT (Figure 1D).
The increased cancellous bone volume in the distal femoral
metaphysis was associated with enhanced bone formation in male
and female PYY2/2 compared to wild-type (Figure 2 A, C). This
was via greater speed (mineral apposition rate, MAR) but not
extent (mineralizing surface, MS) of bone formation. Similarly,
endocortical MAR at the mid-femur was greater in PYY2/2
(representative images Figure 2E), although cortical structure was
not different between genotypes (Table S2). No change was
observed in osteoclast activity, as indicated by osteoclast surface
(Figure 2B, D) or osteoclast number in the distal femoral
metaphysis of PYY2/2 versus wild type mice of either gender.
Adult Onset PYY Over-expression Reduces Bone
Formation and Increases Bone Resorption
Having established that lack of PYY increased bone formation,
we next investigated whether increased levels of PYY, as
commonly seen under anorexic conditions [11,14], have opposing
effects. Elevated PYY is lethal during embryonic development
[36], thus PYY over-expression was induced in adult animals via
a Cre-recombinase activated mechanism (Figure 3A). For this
purpose, inducible PYY transgenic mice (PYYtglox/lox) were
crossed with mice expressing Cre-recombinase under a tamoxi-
fen-inducible promoter located within the ROSA26 locus
(ROSACre). Transgene expression in PYYlox/creERT2 mice (from
now on called PYYtg) was induced in 10 week-old mice, with
tissues collected at 16 weeks of age. Tamoxifen injected PYYtglox/lox
(from now on called WT) mice were used as controls. The presence
and induction of the PYY transgene were confirmed by PCR
on genomic DNA (Figure 3B). PYY mRNA over-expression
was identified in the liver of PYYtg, but not in the liver from
wild-type mice (Figure 3C, D). Immunohistochemical staining
revealed increased staining for PYY protein in the islets of
Langerhans in the pancreas of PYYtg mice compared to wild-type
or PYY2/2 (Figure 3E). PYY mRNA was also over-expressed in
the hypothalamus and, to a lesser extent, in the rest of the brain
(extra-hypothalamus) (Figure 3F). However, central PYY mRNA
levels were still 10-fold lower compared to central mRNA levels
of NPY, the main ligand for Y receptors in the brain, identifying
NPY as the major hypothalamic signal in PYYtg mice, and
suggesting that PYY over-expression in this transgenic model
impacts predominantly peripheral Y receptor signaling also
demonstrated in a recent report showing altered glucose metabolism
in this model [37].
Consistent with our hypothesis that PYY inhibits bone mass,
PYYtg mice displayed a skeletal phenotype essentially opposing
PYY2/2. Lean mass was lower in female PYYtg littermates prior
to tamoxifen (Table S3), the change in body composition was
similar between PYYtg and WT 6 weeks post-injection (Table S4).
At cull, isolated femoral BMD, femoral length and vertebral height
were significantly lower in female PYYtg than control, with similar
trends in male PYYtg (Figure 4A, C). Furthermore, a reduction in
cancellous bone volume was observed specifically in female but not
male PYYtg at the distal femora as well as lumbar vertebrae
(Figure 4B, D, E, F).
Analysis of the distal femoral metaphysis of PYYtg revealed
changes in both bone resorption and formation, indicating a
comprehensive regulation of the bone remodeling cycle by PYY.
Osteoblast activity (MAR) was significantly reduced in both male
and female PYYtg mice compared to wildtype. This is consistent
with the opposite phenotype of enhanced MAR observed in
PYY2/2 mice, and indicates a negative association between PYY
and osteoblast activity. Furthermore, cancellous bone formation
rate and mid-femoral endocortical MAR were significantly lower
in female but not male PYYtg (Figure 5A, C, E), suggesting a more
pronounced effect of PYY on bone, in female mice. In cortical
bone, alterations in cortical MAR in female PYYtg versus control
mice were associated with structural changes as indicated by
reductions in total cross-sectional area, cortical bone area and
mean polar moment of inertia, an index of bone strength (Table
S5). In males, mid-femoral cortical changes were consistent with
females; however they did not reach significance.
In addition to modulating osteoblast activity, PYY over-
expression also affected bone resorbing osteoclasts. PYYtg mice
displayed greater osteoclast surface measured in the femoral
metaphysis of both genders (Figure 5B, D) and greater osteoclast
number in females only mice, despite comparable elevations of
osteoclast number in male PYYtg. Interestingly, these effects of
elevated PYY expression on bone resorption were not observed in
PYY2/2 mice.
The alteration in osteoclast indices suggested the possibility of a
direct action of PYY on these cells. To examine this, Y receptor
expression was assessed in osteoclastic cultures from wild type and
PYY Tg mice. RT-PCR was performed on mRNA isolated from
mature (5 day) cultured osteoclasts employing sets of primers
specific for all known Y-receptors (Y1, Y2, Y4, Y5 and y6).
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Positive signals for all Y-receptors were obtained from mRNA
derived from the brain (Figure 6A). In contrast, no signal for any of
the receptors was detected in osteoclastic mRNA or from bone
marrow macrophages (BMM). Since the Y1R is known to be
expressed in myeloid lineage cells [38] a time course study was
undertaken to examine the potential for early PYY effects. Y1R
expression was absent at all time points through osteoclast
maturation confirming that PYY action on bone is purely
mediated via signalling on osteoblasts.
PYY Signals Directly in Osteoblastic Cells via the Y1
Receptor
In order to examine the mechanism by which PYY may
regulate bone homeostasis, primary calvarial osteoblast cultures
were treated with 50 nM PYY and cellular activation assessed by
examination of ERK phosphorylation. Consistent with a direct
action of PYY on osteoblasts, ERK phosphorylation was rapidly
induced following exposure to PYY (Figure 6B, C). This response
was markedly diminished in the presence of the Y1 receptor-
specific antagonist (1229U91) [34], the only Y receptor known to
be expressed on osteoblasts [39,40,41]. This result confirms a
direct action of PYY on bone cells through Y1 receptors signalling.
To assess the effect of PYY on osteoblast proliferation primary
bone marrow stromal cell (BMSC) cultures were grown in
osteogenic media and treated with 50 nM PYY for 5 days in
which cell number was assessed by the MTS cell proliferation
assay. PYY had no effect upon cell number in either wild type or
Y1 receptor null BMSC cultures (Figure 6D). This result is
consistent with PYY effects upon osteoblast activity (MAR) not
surface extent (MS) evident in both PYY2/2 and PYYtg mice.
Discussion
Recently, our understanding of the interactions between the gut
and bone has increased markedly, with the gastrointestinal/
skeletal interface emerging as an important regulator of bone
Figure 1. Greater bone mass in PYY2/2mice.Male (A) and female (B) PYY2/2mice display no difference in body weight, but greater whole body
BMD, whole body BMC in female mice. Regional analysis revealed greater lumbar BMD and BMC in PYY2/2 of both genders. Representative images of
distal femur histological sections and 3D surface rendered models of mCT scanned lumbar vertebra of male (C) and female (D) mice showing greater
cancellous bone volume in the distal femoral metaphysis of PYY2/2 mice in both genders and in the lumbar vertebral body of female PYY2/2 mice
(D). Mean 6 SEM of 7–18 mice per group are shown. *p,0.05, **88p,0.005 versus wild-type (WT).
doi:10.1371/journal.pone.0040038.g001
Figure 2. Bone cell activities in the femora of PYY2/2 mice. In the distal femoral metaphysis, lack of PYY signaling results in greater bone
formation rate (A,C) due to greater mineral apposition rate (MAR) with no change in mineralizing surface (C,I) in both genders. Endocortical MAR at
the mid femur was also greater in PYY2/2 compared to wild-type. Parameters of cancellous bone resorption as indicated by osteoclast surface and
number (B,D) are similar between PYY2/2 and wild-type controls. Representative images of endocortical MAR are shown in E. Scale bar represents
10 mm. Mean 6 SEM of 5–18 mice per group are shown. *p,0.05, **p,0.005, ***p,0.001 versus wild-type (WT).
doi:10.1371/journal.pone.0040038.g002
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mass. In addition to classic pathways involving calcium balance,
the gut is now recognized for a far more complex regulatory role in
skeletal homeostasis, with a number of gastro-intestinal peptides
identified as regulating bone mass [2]. In the present study we
demonstrate the critical role for the gut-derived satiety hormone
PYY in the maintenance of bone homeostasis. Overproduction of
Figure 3. Evaluation of PYY overproduction. As shown in the schematic diagram of the PYY transgene construct (A), liver genomic DNA was
analyzed for presence of PYY transgene construct (B) and deletion of stop cassette (hence activation of PYY transgene) by southern analysis. Hepatic
PYY mRNA expression was detected only in PYYtg mice and not littermate controls as shown by RT?PCR (C) and qPCR (D). PYY staining (brown) is
more intense in the islets of Langerhans in the pancreas of PYY transgenic than wild-type littermates (E). PYY mRNA levels are greater in PYYtg
hypothalamus and the rest of the brain, compared to wild-type littermates, but are lower compared to NPY mRNA levels of the same genotype (F).
Number of PCR cycles is indicated at right, followed by size of PCR product (B-C). Values shown are normalised to ribosomal protein L13 (RPL-13)
levels and relative to wild-type expression (D, F). n.d., not detected (E). Scale bar represents 50 mm (E). Pictures are representative of staining observed
in tissues obtained from 16-week-old mice (2?3 mice per group) (E). *p,0.05, ***p,0.001 versus wild-type (WT).
doi:10.1371/journal.pone.0040038.g003
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PYY in adult animals reduces bone mass whereas lack of PYY in
mice increases bone mass. Importantly, PYY’s role in the
maintenance of bone mass involves both arms of the bone
remodeling cycle; reducing the formation of bone and increasing
bone resorption, displaying the complexity of the osteo-regulatory
signals coming from the gut.
Our data demonstrate a suppressive effect of PYY on the
activity of bone forming osteoblasts, reducing the rate at which
mineralized tissue is formed by these cells. This effect is evident
throughout the skeleton, with changes in both the dense, structural
cortical bone as well as in the sponge-like and more metabolically
active cancellous bone. However, PYY does not appear to alter the
production of osteoblastic cells in vivo, as indicated by no change in
their surface extent. In vitro studies indicate that PYY does not
affect osteoblast proliferation, a finding consistent with previous
studies of Y1R, Y2R and NPY knockout osteoblasts in culture, all
of which showed no changes prior to 15 days in culture [30,40,41].
In addition to effects on bone formation, PYY altered the surface
extent of the bone resorbing osteoclasts. In a cellular change
evident only following PYY over expression as osteoclasts were
more abundant on the bone surface of PYYtg mice. Interestingly,
the lack of Y receptors in osteoclasts suggests that PYY may
indirectly affect osteoclast activity. Thus elevation in PYY levels
results in dual negative impacts upon the maintenance of bone
mass. In keeping with these changes in bone cell activity, loss of
PYY signaling was associated with significantly increased bone
mass in PYY2/2 mice of both genders. Interestingly, in PYYtg
mice, bone mass was only reduced in female mice. Cellular
Figure 4. Lower bone mass and reduced bone size in female PYYtg mice. Although male PYYtg mice are similar to wild-type littermates (A-
B), female PYYtg mice have lower femoral BMD, femur length, vertebral height and cancellous bone volume of distal femoral metaphysis (C-D);
representative images from male (E) and female (F) mice of distal femoral histological sections and 3D model images of mCT scanned lumbar vertebra.
Mean 6 SEM of 4–12 mice per group are shown. *p,0.05, **p,0.05 versus wild-type (WT).
doi:10.1371/journal.pone.0040038.g004
Figure 5. Bone cell activities in the femora of PYYtg mice. Although cancellous bone volume is lower in female but not male PYYtg,
alterations in bone cell activities are observed in both genders. Mineral apposition rate (MAR) was reduced in both genders (A,C), with bone
formation rate reduced only in females, with no change in mineralizing surface. Endocortical MAR at the mid femur was reduced in female PYYtg
compared to wild-type. Osteoclast surface was greater in both genders of PYYtg and osteoclast number only greater in females. Representative
images of endocortical MAR are shown in E. Scale bar represents 10 mm. Mean 6 SEM of 4–12 mice per group are shown. *p,0.05, **p,0.005,
***p,0.001 versus wild-type (WT).
doi:10.1371/journal.pone.0040038.g005
Peptide YY Regulates Bone Remodeling in Mice
PLoS ONE | www.plosone.org 9 July 2012 | Volume 7 | Issue 7 | e40038
Peptide YY Regulates Bone Remodeling in Mice
PLoS ONE | www.plosone.org 10 July 2012 | Volume 7 | Issue 7 | e40038
changes were consistent across both genders; however, the lack of
change in bone mass in males suggests a potential sex-specific
influence. Taken together, these findings demonstrate that PYY
inhibits osteoblast activity and stimulates osteoclast production in
both cancellous and cortical bone, and the skeletal effects of PYY
are more prominent in female than in male mice.
These findings provide a possible mechanism for the clinical
observation of bone loss in situations associated with elevated
circulating PYY. PYY is considered as a potential contributor to
the low bone mass of anorexia nervosa, where PYY levels are
reported to be increased [14]. Several techniques of bariatric
surgery (gastric sleeve and Roux en Y bypass) may also produce a
marked elevation in PYY responses [19,20], and with it a potential
for exaggerated bone loss in addition to that associated with weight
reduction. Perhaps more importantly, PYY levels have a
significant, negative association with bone mass in healthy
premenopausal women [13]. This suggests that PYY may play a
tonic inhibitory role in bone homeostasis in normal populations, as
well as in those with overt changes in energy homeostasis.
In contrast to our present findings, however, a low bone mass
phenotype was reported in an independently generated PYY2/2
mouse model [6]. Differences between germline knockout models
are not unusual and the reason for the discrepant results in these two
models may relate to a different design of the targeting vector
(insertion of a large reporter gene LacZ versus absence of additional
sequences in our model), some variation in the genetic background
(the origin/background of the ES cells is not given), and the age at
which the analysis of bone was performed (i.e. 3–4 months in our
model compared to 6–9 months in the other model). It is also
important to note that the PYY knockout model generated by
Wortley et al (6) has also a very different phenotype in respect to body
weight and metabolic parameters compared to our model as well as
another one published by Batterham et al [16] both of which
showed increased BW and fat mass and altered glucose homeostasis.
Together, this could have significant influences on bone mass.
Furthermore, although cancellous bone was analyzed by histomor-
phometry in the vertebrae in the initial study, no bone cell activities
or long bone parameters were examined in the previous report (6).
Importantly, our data showing increased bone mass in the
absence of PYY and decreased bone mass when PYY is elevated
are also consistent with findings from knockout models of Y1 and
Y2 receptors [31,32,41,42]. These models have clearly established
that bone mass is under the control of the NPY system, indirectly
via hypothalamic Y2 receptors [31] and NPY-ergic neurons [28],
as well as directly via osteoblastic Y1 receptors [39,41]. While PYY
is ideally placed to signal via both the hypothalamic Y2 receptors
and osteoblastic Y1 receptors, in vitro, PYY signaling was clearly
evident in osteoblasts, stimulating the MAPK pathway, as has
been demonstrated for NPY [39]. Importantly, this effect was
markedly blunted by Y1 receptor antagonism, indicating direct
PYY signaling in osteoblasts via the Y1 receptor. Based upon
previous models, activation of either Y1 or Y2 receptors will lead
to inhibition of bone formation, consistent with reduced osteoblast
activity seen following PYY overproduction. Importantly, PYY is
processed via dipeptidyl peptidase-4 (DPP IV) to the shorter
version, PYY3–36, which shows an altered pharmacological profile.
PYY3–36, like the full length PYY, is able to signal through Y2
receptors, but loses its affinity for the Y1 receptor. This may ensure
that the satiety function of this gut peptide is preserved and
prolonged, while peripheral Y1-mediated actions, such as the
inhibition of bone formation, are attenuated. The ratio of the full-
length versus the truncated version of PYY is likely to be critical in
the normal control of bone mass. From a clinical perspective,
inhibiting the action of DPP IV to prevent inactivation of another
beneficial gut peptide, glucagon-like peptide 1 (GLP-1), might
have negative side effects on bone mass due to concomitant
stabilization of the Y1-active full length PYY.
In summary, detailed analyses using both PYY knockout and
PYY transgenic mouse models demonstrate that PYY exerts a
negative influence upon the maintenance of bone mass, and
mediates its skeletal effects via modulation of osteoblast and
osteoclast activity. Importantly, these findings suggest that the
changes in circulating PYY levels observed in clinical conditions,
such as anorexia nervosa, amenorrhea and patients who have
undergone bariatric surgery [2], may contribute to the alterations
in bone mass in these patients. Moreover, gut derived PYY may
represent a significant regulatory factor in the maintenance of
bone mass in normal populations [13], reinforcing the importance
of the gut-derived endocrine system in skeletal homeostasis.
Modulation of PYY may therefore offer novel avenues for control
of bone mass in specific patient groups, as well as providing insight
into the role of the gut in wider homeostatic processes.
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Figure 6. PYY signalling in osteoblasts via Y1 receptors. Y receptor gene expression was evident in brain tissue, but was absent in bone
marrow macrophages (BMM) or cultured osteoclasts (Oc) from wild type mice(A). Y1R was not detected at any time point throughout RANKL-induced
osteoclast differentiation (A). Calcitonin Receptor (CTR) and Cathepsin K gene expression were used as osteoclast markers. NTC, no template control.
PYY induced signaling in primary calvarial osteoblasts through strong phosphorylation of ERK, a response which was blunted in the presence of Y1
receptor specific antagonist (1229U91). (B) p-ERK, phosphorylated ERK; t-ERK, total ERK from western blots of calvarial cultures. (C) Western blots were
quantified by densitometry of p-ERK and t-ERK bands. Proliferation of osteoblastic cultures from wild type and Y1 receptor null mice were not altered
by PYY (D). Mean 6 SEM of 4 replicates per group are shown.
doi:10.1371/journal.pone.0040038.g006
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